Considering that the hypoxic constriction may lead to CAS and cardiac dysfunction and that PDE1 and PDE5 inhibitors are therapies to treat various disease,43, 44, 45, 46, 47 our data may also provide clinical references with the use of these inhibitors in patients with coronary artery disease exposed to repeated hypoxia (as in the case of sleep apnoea4, 5, 6). Here, PDE5A is linked to coronary artery disorder.